definiens: and ( each as defined in the Material Transfer Agreement ), and all other results, information, data, data analyse s, reports, records, methods, processes, practices, formulae, i nstructions, skills, techniques, procedures, experi ences and developments made by or on behalf of Aevi in the co urse of conducting the Initial Development ( collect ively, ) . For clarity, the SAS datasets from the Studies will be included in the Initial Development Data . The Parties will hold a telephoni c or in person meeting at least once each calendar quarter for sharing updates and discussing action plans on issues related to the Initial Development, includin g, but not limited to, the Studies, and non - GMP process develo pment . Aevi will disclose to KKC any clinical trial data from the Adolescent Study received from the Childre n ’s Hospital of Philadelphia ( ) promptly after Aevi receives such data . Aevi will maintain the Initial Development Data in its database and will upon KKC ’ s request, use good faith efforts to provide KKC with a copy o r an electronic file of the Initial Development Dat a for KKC ’s use within ( * * * ) of receipt of such request . Additionally, upon KKC ’s reasonable request, Aevi w ill provide to KKC a copy or an electronic file of the topline data from the completed Studies in its poss ession within ( * * * ) following receipt of such request . The topline data will consist of the summary tables of efficacy and safety, as defined in the Adolescent Study Prot ocol or COVID Study Protocol, and will be compiled and prepared following database lock and all necessary QA / QC activities